Stereotaxis' new Niobe uses:
This article was originally published in Clinica
Extending its potential market beyond the coronary vasculature, Stereotaxis can now use its Niobe magnetic navigation system in neurovascular and peripheral applications. The Niobe has been cleared for use with the firm's family of Cronus magnetically enabled 0.014 inch vascular guidewires. "While we have no current plans to immediately move into peripheral and neurovascular clinical applications, this clearance provides us with the flexibility to do so at a time of our choosing," said Bevil Hogg, the St Louis, Missouri company's president and CEO.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.